Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Cel-Sci Corporation (CVM : AMEX)

• Company Description    CEL-SCI CORP. was formed to acquire and finance research and development of natural human interleukin-2 (``IL-2``) and lymphokine-related products and processes using the Co.'s proprietary cell culture technologies. The Co.'s proprietary product is sometimes referred to as MULTIKINEn, or buffy-coat interleukins, which is a combination, or ``cocktail`` of IL-2 and certain lymphokines and cytokines. MULTIKINE is a trade name of Co. Since its inception the focus of the Co.'s product development efforts has been on conducting clinical trials to test its proprietary technologies. Number of Employees:

• Price / Volume Information    Yesterday's Closing Price: $5.26 Daily Weekly Monthly 20 Day Moving Average: 63,898 shares Shares Outstanding: 8.41 (millions) Market Capitalization: $44.23 (millions) Beta: 0.54 52 Week High: $20.41 52 Week Low: $1.98 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -16.38% -16.23% 12 Week -47.03% -47.88% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 8229 BOONE BLVD . SUITE 802 - VIENNA,VA 22182 USA ph: 703-506-9460 fax: 703-506-9471 gdewindt@cel-sci.com http://www.cel-sci.com

• General Corporate Information    Officers Geert Kersten - Chief Executive Officer and Treasurer Robert Watson - Chairman Patricia B. Prichep - Chief Financial Officer and Chief Operating Office John Cipriano - Senior Vice President Bruno Baillavoine - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 150837706 SIC: 2836 Fiscal Year Fiscal Year End: September Last Reported Quarter: 06/01/25 Next Expected EPS Date: 02/13/26 Share - Related Items Shares Outstanding: 8.41 Most Recent Split Date: 5.00 (0.03:1) Beta: 0.54 Market Capitalization: $44.23 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 02/13/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.27 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 67.65% vs. Previous Quarter: 43.39% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 12/31/25 - - 09/30/25 - -240.36 06/30/25 - -259.38 ROA 12/31/25 - - 09/30/25 - -105.88 06/30/25 - -107.21 Current Ratio 12/31/25 - - 09/30/25 - 2.26 06/30/25 - 0.47 Quick Ratio 12/31/25 - - 09/30/25 - - 06/30/25 - 0.37 Operating Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Net Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Pre-Tax Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Book Value 12/31/25 - - 09/30/25 - - 06/30/25 - 1.32 Inventory Turnover 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00 Debt-to-Equity 12/31/25 - - 09/30/25 - 0.36 06/30/25 - 0.89 Debt-to-Capital 12/31/25 - - 09/30/25 - 26.26 06/30/25 - 47.17

Powered by Zacks Investment Research ©